1 2
play

1 2 What subtype of cutaneous melanoma is most common in A Quick - PDF document

Disclosure I have no relevant financial relationships with any companies related to the content of this course. Acute and Chronic Immune-Related Toxicities Implications for Long-Term Cancer Survivors Katy K. Tsai, MD Assistant Clinical


  1. Disclosure I have no relevant financial relationships with any companies related to the content of this course. Acute and Chronic Immune-Related Toxicities Implications for Long-Term Cancer Survivors Katy K. Tsai, MD Assistant Clinical Professor Melanoma & Skin Cancer Program 8 th Asian Health Symposium 10/10/19 1 2 What subtype of cutaneous melanoma is most common in A Quick Poll… Asians? Superficial spreading melanoma A. Acral lentiginous melanoma B. Lentigo maligna melanoma C. Nodular melanoma D. 3 4 3 4 1 | [footer text here]

  2. Acral lentiginous melanoma This Session § Immunotherapy – What is it? § Immune-Related Adverse Events - Mechanisms of Toxicity - Management § Best Practices & Survivorship § Questions 5 6 5 6 This Session Immunotherapy is not Chemotherapy § Immunotherapy – What is it? § Immune-Related Adverse Events = - Mechanisms of Toxicity - Management § Best Practices & Survivorship § Questions 7 8 Prsentation Title 7 8 2 | [footer text here]

  3. Immune Checkpoint Inhibition (ICI) FDA-approved Immune Checkpoint Inhibitors Priming phase Anti-CTLA-4 Effector phase Anti-PD-1/L1 Figure adapted from Abdul Abbas, MD 9 10 9 10 This Session Immune-Related Adverse Events (irAEs) § Immunotherapy – What is it? § Unique spectrum of side effects arising from general immune system enhancement § Immune-Related Adverse Events - Mechanisms of Toxicity - Management § Best Practices & Survivorship § Questions Enstoff et al, Future Oncology 2017. 11 12 11 12 3 | [footer text here]

  4. GENERAL • Fatigue Possible Mechanisms of Toxicity PULMONARY • Infusion reactions • Pneumonitis OCULAR • Uveitis/scleritis • Conjunctivitis DERMATOLOGIC • Rash • Pruritus CARDIAC • Vitiligo • Myocarditis • SJS/TEN • Arrhythmias RHEUMATOLOGIC ENDOCRINE • Arthralgias/myalgias • Hypophysitis • Myositis • Thyroiditis (hyper/hypo) • Sicca syndrome • Adrenal insufficiency • Diabetes (Type I) RENAL • Nephritis (acute tubulointerstitial) GASTROINTESTINAL NEUROLOGIC • Diarrhea/colitis • Motor/sensory neuropathy • Hepatitis HEMATOLOGIC • Guillain-Barré syndrome • Pancreatitis • Thrombocytopenia • Autoimmune encephalitis • Neutropenia • Red cell aplasia • Aseptic meningitis • Myasthenia gravis • Cryoglobulinemia Postow et al, N Engl J Med 2018. 13 14 13 14 Classifying Acute vs. Chronic Classifying Severity Weber J et al, JCO 2012, 2017. 15 16 15 16 4 | [footer text here]

  5. For Example… General Management 17 18 17 18 Which immune checkpoint inhibitor regimen has a higher irAE Incidence incidence of side effects, and/or more severe side effects? Ipilimumab A. Nivolumab B. Ipilimumab + nivolumab C. Pembrolizumab D. Larkin J et al. N Engl J Med 2015. 19 20 19 20 5 | [footer text here]

  6. All immune-related adverse events eventually resolve. Time to Resolution of Grade 3-4 irAEs True A. False B. Endocrine Skin GI Sznol M et al, JCO 2017. 21 22 21 22 This Session § Immunotherapy – What is it? § Immune-Related Adverse Events - Mechanisms of Toxicity - Management § Best Practices & Survivorship Implications § Questions 24 23 24 6 | [footer text here]

  7. Best Practices Best Practices PATIENT Education PROVIDER Education § Empower early symptom reporting § Risk assessment for side effects § Address integrative medicine concerns - Pre-existing autoimmune illness? Organ transplant? § Address family planning concerns - Long-term steroid use § “Post-treatment teaching” - Medication reconciliation - Transition from oncology to primary care § Resources for irAE management - Published consensus guidelines - Continuing education workshops Brahmer et al. JCO 2017. Puzanov et al. JITC 2017. 25 26 NCCN Guidelines for the Management of Immunotherapy-Related Toxicities. 25 26 Takeaway Points Thank you! katy.tsai@ucsf.edu § You will care for patients who ARE RECEIVING immunotherapy, or who HAVE RECEIVED immunotherapy and are re-integrating into primary care. § Overall survival has improved in so many different cancers! Continued age- appropriate cancer surveillance and HEALTH MAINTENANCE should continue. § Be willing to investigate unusual complaints. Immune-related adverse events can be ATYPICAL and/or LATE. § Don’t hesitate to phone a friend. Current guidelines are expert consensus-driven rather than evidence-based (for now). 27 27 28 7 | [footer text here]

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend